SOUTH
SAN FRANCISCO, California and VANCOUVER,
Canada, Sept. 13,
2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the
"Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company
focused on developing novel therapies for the treatment of prostate
cancer, today announced the appointment of Philip Kantoff, M.D., to its Board of Directors.
Dr. Kantoff brings invaluable insight and experience to ESSA as a
renowned medical oncologist and leader in the clinical development
of new prostate cancer treatments.
"Phil's breadth and quality of accomplishments are unmatched,
and we are honored to welcome him to ESSA's Board of Directors,"
stated Richard M. Glickman, L.L.D.
(Hon), Chairman of ESSA's Board of Directors. "We are eager to
leverage Phil's admirable expertise in prostate cancer clinical
research, as we work to further ESSA's pipeline of first-in-class
anitens targeting the N-terminal domain of the androgen
receptor."
"ESSA's development program is focused on uniquely interfering
with androgen-driven prostate cancer through targeting of the
N-terminal domain of the androgen receptor. I look forward to
advising and working with ESSA's Board of Directors and management
team during this pivotal time," said Philip
Kantoff, M.D.
Dr. Kantoff currently serves as the Chief Executive Officer and
Co-founder of Convergent Therapeutics, where he spearheads the
development of precision radiopharmaceuticals for prostate cancer
treatment. Previously, Dr. Kantoff served as Chairman of the
Department of Medicine at Memorial Sloan Kettering Cancer Center
(MSK), managing more than 450 physicians and physician-scientists,
while caring for patients, running a funded laboratory and
developing improved cancer therapies. Prior to MSK, he was
Professor of Medicine at Harvard Medical
School and the Jerome and Nancy Kohlberg Chair at
Harvard Medical School, Director of the
Lank Center for Genitourinary Oncology at the Dana-Farber Cancer
Institute and Division Head of Solid Tumor Oncology, serving as
principal investigator in significant trials developing new
therapeutic targets for patients with advanced prostate cancer.
During this time, Dr. Kantoff conducted laboratory research focused
on the genetic epidemiology of prostate cancer, mechanisms of
resistance, the role of noncoding RNAs in prostate cancer, and the
discovery of biomarkers as potential prognostic tools and/or
therapeutic targets. Dr. Kantoff earned both his undergraduate and
medical degrees from Brown University
and is board certified in internal medicine and medical oncology.
He has written more than 500 articles and books and is the
recipient of numerous awards celebrating his research and clinical
skills.
About ESSA Pharma Inc.
ESSA is a clinical-stage pharmaceutical company focused on
developing novel and proprietary therapies for the treatment of
patients with prostate cancer. For more information, please visit
www.essapharma.com and follow us on Twitter under @ESSAPharma.
Forward-Looking Statement
Disclaimer
This release contains certain information which, as presented,
constitutes "forward-looking information" within the meaning of the
Private Securities Litigation Reform Act of 1995 and/or applicable
Canadian securities laws. Forward-looking information involves
statements that relate to future events and often addresses
expected future business and financial performance, containing
words such as "anticipate", "believe", "plan", "estimate",
"expect", and "intend", statements that an action or event "may",
"might", "could", "should", or "will" be taken or occur, or other
similar expressions and includes, but is not limited to, the
Company's plans to leverage Mr. Kantoff's expertise, plans to
further ESSA's pipeline and the Company's development program.
Forward-looking statements and information are subject to
various known and unknown risks and uncertainties, many of which
are beyond the ability of ESSA to control or predict, and which may
cause ESSA's actual results, performance or achievements to be
materially different from those expressed or implied thereby. Such
statements reflect ESSA's current views with respect to future
events, are subject to risks and uncertainties and are necessarily
based upon a number of estimates and assumptions that, while
considered reasonable by ESSA as of the date of such statements,
are inherently subject to significant medical, scientific,
business, economic, competitive, political and social uncertainties
and contingencies. In making forward looking statements, ESSA may
make various material assumptions, including but not limited to (i)
the accuracy of ESSA's financial projections; (ii) obtaining
positive results of clinical trials; (iii) obtaining necessary
regulatory approvals; and (iv) general business, market and
economic conditions.
Forward-looking information is developed based on assumptions
about such risks, uncertainties and other factors set out herein
and in ESSA's Quarterly Report on Form 10-Q dated August 4, 2022 under the heading "Risk Factors",
a copy of which is available on ESSA's profile on EDGAR
at www.sec.gov and on the SEDAR website at www.sedar.com,
and as otherwise disclosed from time to time on ESSA's EDGAR and
SEDAR profiles. Forward-looking statements are made based on
management's beliefs, estimates and opinions on the date that
statements are made and ESSA undertakes no obligation to update
forward-looking statements if these beliefs, estimates and opinions
or other circumstances should change, except as may be required by
applicable United States and
Canadian securities laws. Readers are cautioned against attributing
undue certainty to forward-looking statements.
View original
content:https://www.prnewswire.com/news-releases/essa-pharma-appoints-philip-kantoff-to-its-board-of-directors-301622518.html
SOURCE ESSA Pharma Inc